The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

a study on Depression

Summary

for people ages 18-55 (full criteria)
at San Diego, California and other locations
study started
estimated completion
Sidney Zisook

Description

Summary

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

Details

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study

Keywords

Treatment Resistant Depression Depression Depressive Disorder Depressive Disorder, Treatment-Resistant Psilocybin

Eligibility

For people ages 18-55

Upper age limit of 55 years is applicable only to USA sites

Inclusion Criteria:

  • Diagnosis of TRD

Exclusion Criteria:

  • Other comorbidities

Locations

  • Altman Clinical and Translational Research Institute, University of California accepting new patients
    San Diego California 92093 United States
  • Kadima Neuropsychiatry Institute accepting new patients
    La Jolla California 92037 United States

Lead Scientist

  • Sidney Zisook
    Sidney Zisook, M.D., is director of the University of California, San Diego Residency Training Program, and a Distinguished Professor of Psychiatry at UCSD. Dr. Zisook received his Bachelor of Arts from the University of California at Berkeley and his medical degree from Stritch-Loyola, Chicago.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
COMPASS Pathways
ID
NCT03775200
Phase
Phase 2
Study Type
Interventional
Last Updated